Speaker Profile
Biography
Dr Gaedigk, a distinguished researcher and professor, has made significant contributions to the field of pharmacogenomics. Her work has been instrumental in advancing our understanding of drug metabolism and its implications for personalized medicine. She has characterized the CYP2D6 gene locus across ethnically diverse populations discovering numerous allelic variants, enhancing our understanding of genetic diversity and its impact on drug response. Dr. Gaedigk has also developed the activity score system, a method facilitating genotype interpretation, which has been adopted in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and is widely used in pharmacogenomics implementation. This innovative approach has significantly improved the accuracy of pharmacogenomic testing, enabling more precise predictions of individual drug responses. In addition to her research, Dr. Gaedigk serves as the Director of the Pharmacogene Variation Consortium (PharmVar), a pharmacogene data repository. Under her leadership, PharmVar provides pharmacogenomics gene nomenclature, serving as a vital resource for researchers and clinicians worldwide.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair:
Kelly E. Caudle, St. Jude
The PMWC 2024 Pharmacogenomics (PGx) Track focuses on advancing standardization in pharmacogenomics to achieve better clinical outcomes. The importance of standardization in PGx cannot be overstated as it can help to improve patient care in several ways. Standardization of clinical laboratory processes can help ensure consistent and accurate test results, which is crucial for making informed clinical decisions. Standardization of reporting can help to ensure that test results are communicated in a clear and understandable manner to clinicians and patients. Standardization of pharmacogenomic test ordering and reimbursement can help to ensure that patients have access to the tests they need, regardless of their location or financial situation. Standardization of PGx education can help to ensure that healthcare professionals have the knowledge and skills they need to use PGx in clinical practice effectively. Finally, clinical pearls and outcome data can help to demonstrate the value of PGx in improving patient outcomes and informing clinical decision-making.
- PMWC 2024 PGx Award Ceremony:
Pioneer Honoree: Andrea Gaedigk, Children’s Mercy Research Institute (CMRI)
Luminary Honoree: Teri E. Klein, Stanford - Standardization: Key to Advancing Precision Medicine
Opening Talk: Kelly E. Caudle, St. Jude
- Current and Desired States of Standardization of Clinical Laboratory Processes
Chair: Andrea Gaedigk, Children’s Mercy Research Institute (CMRI)
- Vicky Pratt, Agena Bioscience
- FIRESIDE CHAT
Chair: Damon Hostin, Illumina
- Howard McLeod, Utah Tech University
- Current and Desired States of Standardization of Reporting (PANEL)
Chair: Chad Bousman, University of Calgary
- Lisa Brown, Great Scott!
- Vicky Pratt, Agena Bioscience
- Current and Desired States of Standardization of Pharmacogenomic Test Ordering and Reimbursement (PANEL)
Chair: Sara Rogers, American Society of Pharmacovigilance
- Jai Patel, Atrium Health
- Greg Warren, Axene Health Partners - Current and Desired State of PGx Education
Chair: Phil Empey, University of Pittsburgh
- Michelle Whirl Carrillo, Stanford
- Current and Desired State of the Patient Experience in Precision Medicine (PANEL)
Chair: Avni Santani, LetsGetChecked
- Kristy Crooks, University of Colorado - Stuart Scott, Stanford - Clinical Pearls and Outcome Data: Advancing the Adoption of Pharmacogenomics in Clinical Practice
Chair: Kelly E. Caudle, St. Jude
- Larisa H Cavallari, University of Florida
- Jeff Bishop, University of Minnesota - PMWC Showcase
- Bani Tamraz, UCSF